VIRIDIAN THERAPEUTICS, INC.\DE (VRDN)
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Duke Energy reports first-quarter 2026 financial results
4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors
Bowhead Specialty Holdings Inc. Reports First Quarter 2026 Results
WEC Energy Group reports first-quarter results
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
Biotech Leaders Launch National Alliance to Define the Future of American Innovation
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
D-Wave Announces Qubits Europe 2026 Quantum Computing User Conference
42% of Consumers Now Use AI Tools to Shop, NIQ Data Shows